NEXGEL Announces Data From Randomized, 30-Patient, Single-Center IRB Clinical Study, Funded By Innovative Optics

The study concluded that NEXGEL's hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control

The study was published in Lasers in Surgery and Medicine, 2026

LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical study, funded by Innovative Optics, a leading supplier of safety products and personal protective equipment for medical, surgical and aesthetic healthcare facilities globally.

Positive data from the study detailed a 95.6% reduction in plume concentration compared to the control side (p = 0.0001). Additionally, at 90 days posttreatment, the interventional site demonstrated a 37.2% mean reduction in hair density versus 26.7% on the control side (p = 0.3607). Mean pain scores were also significantly lower on the intervention side (3.5 vs. 5.1, p = 0.0033), with no adverse events were reported.

The study data was published in Lazers in Surgery and Medicine, 2026 by Barry E. DiBernardo, Gabriella A. DiBernardo and Jason N. Pozner on March 30, 2026.

The study was conducted at the Florida Clinical Research Center by plastic surgeons Dr. Barry DiBernardo and Dr. Jason Pozner. It was designed to address a critical health hazard associated with laser hair removal, the release of carcinogenic airborne particles and organic compounds "plume" when hair is vaporized by lasers. If inhaled, the plume may affect short- and long-term health of professionals.